Blood and reported desire
PT-141 half-life and duration
One timing comes from blood sampling. Another comes from women describing desire. The distinction is small on the page and large in its consequences.
Blood measurements
The bremelanotide prescribing information gives a terminal half-life of approximately 2.7 hours, with a 1.9–4.0 hour range, after subcutaneous administration. Half-life describes the time for the concentration in blood to fall by half during the terminal decline. It does not mean the blood contains no drug when that interval ends.
Median peak concentration occurs at approximately 0.5–1.0 hour. Serum protein binding is approximately 21%. These describe the drug's movement and distribution, the subject called pharmacokinetics. I prefer these modestly named measurements to the much larger promise implied by a question about exactly how long something lasts.
Duration in the imaging experiment
How long does PT-141 last? The 2022 imaging study in 31 premenopausal women with HSDD measured increased reported sexual desire for up to 24 hours. The study also observed changes in brain processing. That supplies a human duration finding, alongside the much shorter terminal half-life on the label.
The individual beginning and ending remain unresolved by these measurements. A group-level blood measurement and the period studied for a reported feeling give useful information without specifying when an individual experience begins or ends. Anecdotal accounts add widely varying impressions of duration; they are not clinical evidence and provide no dependable timetable.
The early nasal spray
In the early intranasal study in men, median time to peak concentration was 0.50 hours and terminal half-life was 1.85–2.09 hours. First erections were reported at roughly 30 minutes. Those observations came from an early formulation and an erectile-response study.
Nasal-spray development was discontinued because the amount reaching the bloodstream varied too much. The later approved formulation used subcutaneous delivery. Here the development took a practical turn: an interesting response still leaves a delivery problem to solve. The dosage page follows the formulations without giving preparation instructions.
Breakdown and excretion
The body opens the peptide's ring by hydrolyzing its amide bonds and then breaks the fragments down with peptidases. Those are enzymes that digest peptides. The label reports a volume of distribution of 25.0 L and clearance of 6.5 L/hr; these are pharmacokinetic quantities, rather than volumes administered to a person.
In the radiolabeled excretion study described on the label, 64.8% was recovered through the renal route and 22.8% through feces. The bulk is cleared within roughly a day. Clearance cannot by itself settle the separate questions of drug interactions, cardiovascular suitability or how long desire feels different.